Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

por Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Vicentini, Roberto, Ficorella, Corrado, Ricevuto, Enrico
Publicado 2013

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment...

por BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Publicado 2013

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

por BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Publicado 2014

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

por Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Manetta, Rosa, Vicentini, Roberto, Carducci, Sergio, Saltarelli, Patrizia, Iapadre, Nerio, Coletti, Gino, Ficorella, Corrado, Ricevuto, Enrico
Publicado 2014

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

por Bruera, Gemma, Di Staso, Mario, Bonfili, Pierluigi, Galvano, Antonio, Manetta, Rosa, Coletti, Gino, Vicentini, Roberto, Guadagni, Stefano, Ficorella, Corrado, Di Cesare, Ernesto, Russo, Antonio, Ricevuto, Enrico
Publicado en Oncotarget (2018)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

por Cortellini, Alessio, Cannita, Katia, Parisi, Alessandro, Lanfiuti Baldi, Paola, Venditti, Olga, D’Orazio, Carla, Dal Mas, Antonella, Calvisi, Giuseppe, Giordano, Aldo V, Vicentini, Vincenzo, Vicentini, Roberto, Felicioni, Lara, Marchetti, Antonio, Buttitta, Fiamma, Russo, Antonio, Ficorella, Corrado
Publicado en Onco Targets Ther (2019)